OLMA
Olema Pharmaceuticals Inc
NASDAQ: OLMA · HEALTHCARE · BIOTECHNOLOGY
$14.14
-3.08% today
Updated 2026-04-29
Market cap
$1.23B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.87
Dividend yield
—
52W range
$4 – $36
Volume
1.6M
Olema Pharmaceuticals Inc (OLMA) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — |
| Cost of revenue | $8244.00 | $9033.00 | $11000.00 | $1.66M | $1.66M | $377000.00 | $393000.00 | — |
| Gross profit | $-8244.00 | $-9033.00 | $-11000.00 | $-1.66M | $-1.66M | $-377000.00 | $-393000.00 | — |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $1.69M | $3.92M | $13.70M | $51.10M | $82.27M | $86.14M | $124.52M | $157.70M |
| SG&A | $386000.00 | $403000.00 | $7.82M | $20.39M | $24.71M | $18.82M | $17.74M | $21.00M |
| Operating income | $-2.08M | $-4.32M | $-21.53M | $-71.49M | $-106.99M | $-104.96M | $-142.26M | $-178.70M |
| Operating margin | — | — | — | — | — | — | — | — |
| EBITDA | $-2.16M | $-4.31M | $-21.52M | $-71.33M | $-106.63M | $-104.58M | $-141.87M | $-178.21M |
| EBITDA margin | — | — | — | — | — | — | — | — |
| EBIT | $-2.17M | $-4.32M | $-21.53M | $-71.49M | $-106.99M | $-104.96M | $-142.26M | $-178.70M |
| Interest expense | $28000.00 | $0.00 | $653000.00 | $232000.00 | $357000.00 | — | — | — |
| Income tax | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-2.20M | $-4.32M | $-22.12M | $-71.10M | $-102.59M | $-96.66M | $-129.47M | $-162.45M |
| Net income growth (YoY) | — | -96.4% | -412.5% | -221.4% | -44.3% | +5.8% | -34.0% | -25.5% |
| Profit margin | — | — | — | — | — | — | — | — |